CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Springer Nature
Abstract
The goal of this review is to firstly address the concept of chimeric antigen receptor T-cell (CAR T-cell) therapy and where it fits in the evolving landscape of the management of patients with refractory/relapsed diffuse large B-cell lymphoma. The recognition of the indications for CAR T-cell therapy for patients with aggressive B-cell lymphoma will be discussed, including a review of the algorithms and selection criteria for CAR T-cell therapy and finally, the role of bridging therapy and the timing of CAR T-cell therapy in augmenting chances of a successful outcome. © 2020, The Author(s), under exclusive licence to Springer Nature Limited.
Description
Keywords
Axicabtagene ciloleucel, Chimeric antigen receptor, Lisocabtagene maraleucel, Lisocel, Tisagenlecleucel t, Aplasia, B cell lymphoma, Cancer chemotherapy, Cancer grading, Cancer patient, Cancer recurrence, Cancer regression, Cancer survival, Chimeric antigen receptor t-cell immunotherapy, Clinical effectiveness, Clinical outcome, Cytopenia, Diffuse large b cell lymphoma, Disease activity, Human, Immunoglobulin deficiency, Neurotoxicity, Opportunistic infection, Patient care, Patient safety, Patient selection, Priority journal, Protein expression, Review, Salvage therapy, T cell depletion, T lymphocyte activation, Treatment indication, Tumor lysis syndrome